Avista to invest $92 mln in merger of AHPAC and Organogenesis
Avista has agreed to invest $92 million in the merger of Avista Healthcare Public Acquisition Corp, a blank check company backed by Avista Capital and Organogenesis Inc, a maker of product solutions for the advanced wound care, surgical and sports medicine sectors. When the merger closes, Organogenesis will trade on the NASDAQ under the ticker symbol "ORGO." Credit Suisse Securities (USA) LLC is serving as financial adviser to AHPAC on the deal.
20 August 2018•4 mins read
